gip/glp-1 agonists The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Targeting GLP-1, GIP & GCG

Both tirzepatide (since 2022) and semaglutide (since 2024) were placed on the shortage list, prompting a surge in sales of compounded alternatives

GLP-1 Up supports your bodys natural GLP-1 production the hormone that helps regulate appetite, blood sugar, and energy

FINALLY an advanced blend of plant extracts scientifically shown to promote GLP-1 production & reduce cravings, appetite & visceral fat with healthy diet & exercise.

Emerging applications include non-alcoholic fatty liver disease and neurodegenerative conditions

This review article discusses the possible mechanisms tirzepatide may use to improve cardiovascular health